PERSIST研究:古塞奇尤单抗与乌司奴单抗治疗银屑病第104周结果
PERSIST为德国前瞻性非干预真实世界研究,纳入成人中重度斑块状银屑病患者,分别接受古塞奇尤单抗(302例)或乌司奴单抗(313例)治疗。两队列疾病活动度与生活质量改善维持至第104周,未发现新安全性信号;倾向性评分匹配后古塞奇尤单抗的PASI改善优于乌司奴单抗。
要点
- 两药疾病活动度与生活质量改善均可维持至第104周
- 匹配后古塞奇尤单抗PASI90为65.6%、乌司奴单抗为56.0%
- 古塞奇尤单抗在生物制剂初治患者中PASI90达77.1%,高于经治患者的53.4%
核心结论
- 乌司奴单抗与古塞奇尤单抗带来的医生评估和患者报告结局改善可持续长达2年,未发现新安全性信号。
- 倾向性评分匹配后,古塞奇尤单抗较乌司奴单抗在PASI结局上观察到更大改善。
- 古塞奇尤单抗的改善在生物制剂初治患者中最高,凸显早期治疗的价值。
研究设计与样本
- PERSIST为前瞻性、非干预性、德国多中心真实世界研究,研究对象为成人中重度斑块状银屑病患者。
- 患者按常规临床实践接受古塞奇尤单抗或乌司奴单抗治疗,结局分别在各队列中评估至第104周。
- 另在倾向性评分匹配后对古塞奇尤单抗与乌司奴单抗结局进行事后探索性分析。
主要发现
- 总体分别有302例和313例患者接受古塞奇尤单抗和乌司奴单抗治疗。
- 古塞奇尤单抗组64.7%和63.6%、乌司奴单抗组54.6%和64.4%的患者分别达到PASI90应答和DLQI 0/1评分。
- 倾向性评分匹配后除既往生物制剂使用外基线特征均衡,既往生物制剂使用在古塞奇尤单抗组高于乌司奴单抗组(51.7% vs. 32.0%)。
- 第104周PASI≤1在古塞奇尤单抗组较乌司奴单抗组更常见(58.7% vs. 49.7%)。
- 第104周PASI90应答率古塞奇尤单抗为65.6%、乌司奴单抗为56.0%,PASI100分别为44.3%和28.5%。
临床怎么用
- 真实世界数据支持古塞奇尤单抗与乌司奴单抗在中重度斑块状银屑病中维持至第104周的疗效与生活质量改善。
- 倾向性评分匹配后古塞奇尤单抗PASI结局优于乌司奴单抗,生物制剂初治患者改善最高。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PERSIST was a prospective, non-interventional, real-world study of guselkumab and ustekinumab in adult patients with moderate-to-severe plaque psoriasis in Germany. OBJECTIVES: To examine effectiveness, safety and quality-of-life (QoL) outcomes to Week (W) 104 of treatment with guselkumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. METHODS: Patients (≥18 years of age) received guselkumab or ustekinumab as per routine clinical practice. Outcomes to W104 were examined separately in guselkumab and ustekinumab recipients. An ad hoc exploratory analysis of outcomes with guselkumab versus ustekinumab was also performed following propensity score matching. RESULTS: Overall, 302 and 313 patients received guselkumab and ustekinumab, respectively. Patients in both cohorts experienced improvements in disease activity and QoL that were maintained to W104, with 64.7% and 63.6% of guselkumab- and 54.6% and 64.4% of ustekinumab-treated patients achieving a Psoriasis Area and Severity Index (PASI) 90 response and a Dermatology Life Quality Index (DLQI) 0/1 score, respectively. Propensity score matching yielded well-balanced baseline characteristics except for prior biologic use, which was higher in guselkumab versus ustekinumab recipients (51.7% vs. 32.0%). Achievement of PASI ≤1 at W104 was more common in guselkumab versus ustekinumab recipients (58.7% vs. 49.7%). The W104 PASI90 response rate was 65.6% with guselkumab and 56.0% with ustekinumab; corresponding rates for PASI100 were 44.3% and 28.5%. In guselkumab recipients, response rates were higher in biologic-naïve versus biologic-experienced patients (PASI90, 77.1% vs. 53.4%; PASI100, 55.0% vs. 33.0%). A high level of response for QoL outcomes was observed for both treatments. CONCLUSIONS: Ustekinumab and guselkumab led to improvements in physician-assessed and patient-reported outcomes that were sustained for up to 2 years, with no new safety signals identified. Following propensity score matching, greater improvements in PASI outcomes were observed with guselkumab versus ustekinumab. Improvements with guselkumab were highest in biologic-naïve patients, highlighting the value of early treatment.
引用
- Gerdes S, Hoffmann M, Asadullah K, et al. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study. J Eur Acad Dermatol Venereol. 2023. PMID: 37462295. doi:10.1111/jdv.19296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。